[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multiple-myeloma-mm-lymphoma-large-b-cell-diffuse-dlbcl-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multiple-myeloma-mm-lymphoma-large-b-cell-diffuse-dlbcl-lymphoma":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,56,85,107,162,198,232],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":34,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":4},"100652151","phase-2-baff-car-t-cells-lmy-920-for-treatment-of-relapsed-or-refractory-non-hodgkin-lymphoma-and-multiple-myeloma-100652151",false,"NCT07771361","BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma","Phase 2 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed\u002FRefractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)","Inclusion Criteria:\n\n1. Histologically confirmed:\n\n   a. B cell NHL (Including but not limited to diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia and small lymphocytic lymphoma) i. Relapsed after 2 or more lines of therapy, or ii. Have disease refractory to prior chemotherapy (defined as progressive disease or stable disease lasting ≤ 6 months, as best response to most recent chemotherapy regimen; or disease progression, or recurrence ≤ 12 months after prior autologous stem cell transplantation (ASCT).\n\n   iii. At least one measurable lesion according to Lugano Revised Response Criteria for Malignant Lymphoma.\n\n   OR b. MM i. Relapsed or refractory after 3 or more lines of therapy including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody.\n\n   ii. Measurable disease per IMWG uniform response criteria\n2. No evidence of CNS lymphoma.\n3. Participant is ≥ 18 years of age.\n4. ECOG Performance status ≤ 2.\n5. \\> 2 weeks since prior radiation therapy or systemic therapy at the time of leukapheresis. Patients with mantle cell lymphoma that can only remain stable with continuation of prior BTK inhibitor may continue these agents up to 48 hours prior to apheresis.\n6. Adequate organ function as defined by:\n\n   1. Total bilirubin ≤ 1.5× institutional upper limit of normal (except in patients with Gilbert's syndrome, active hemolysis or disease involvement of the liver.)\n   2. AST (SGOT)\u002FALT ≤ 2.5 × institutional upper limit of normal.\n   3. Calculated creatinine clearance ≥ 30ml\u002Fmin.\n   4. Cardiac ejection fraction of ≥ 50%\n   5. Adequate pulmonary function as defined as pulse oximetry ≥ 92% on room air.\n7. Subjects (or legal guardians) must have the ability to understand and the willingness to sign a written informed consent document.\n8. For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of \\\u003C 1% per year during the treatment period and for at least 6 months after the BAFF CAR-T cell infusion.\n9. For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures with a failure rate of \\\u003C 1% per year during the treatment period , and agreement to refrain from donating spermfor at least 6 months after the BAFF CAR-T cell infusion.\n\nExclusion Criteria:\n\n1. ASCT within 6 weeks prior to informed consent.\n2. History of allogeneic transplantation.\n3. Active graft-versus-host disease.\n4. Active central nervous system or meningeal involvement by lymphoma or leukemia. Subjects with untreated brain metastases\u002FCNS disease will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Patients with a history of CNS or meningeal involvement must be in a documented remission by CSF evaluation and contrast-enhanced MRI imaging for at least 90 days prior to enrollment.\n5. Known active additional malignancies which require systemic treatment (non-immediately morbid malignancies receiving only low-toxicity regimens such as hormone suppression for prostate or breast cancer may be allowed at the judgment of the investigator.)\n6. Less than 28 days elapsed between prior treatment with investigational agent(s) and the day of lymphocyte collection.\n7. Cardiovascular disorders including symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmias, myocardial infarction or stroke (including transient ischemic attack, or other ischemic event).\n8. Active infection requiring intravenous systemic treatment.\n9. HIV seropositivity.\n10. Pregnant or breastfeeding women are excluded from this study.\n11. Evidence of myelodysplasia or cytogenetic abnormality indicative of myelodysplasia on any bone marrow biopsy prior to initiation of therapy.\n12. Serologic status reflecting active hepatitis B or C infection. Patients that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. (PCR positive patients will be excluded.)\n13. Patients with history of active and clinically relevant CNS pathology such as epilepsy, seizure disorders, paresis, aphasia, uncontrolled cerebrovascular disease, severe brain injuries, dementia and Parkinson's disease.\n14. Subjects with uncontrolled intercurrent illness or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n15. History of autoimmune disease (i.e., rheumatoid arthritis, systemic lupus erythematosus) with requirement of immunosuppressive medications (other than low dose steroids) within 2 months.","ALL","18 Years",{"count":19,"type":20},90,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against relapsed or refractory B cell non-Hodgkin lymphoma and multiple myeloma, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cells) can become another strategy to treat refractory lymphoma, even after relapse following cluster of differentiation antigen 19 (CD19) targeting CAR-T treatment.\n\nThis Phase 2 study will establish the safety and efficacy profile of LMY-920.",[26,27,28,29,30,31,32,33],"Non-Hodgkin Lymphoma Refractory\u002F Relapsed","Multiple Myeloma Refractory","Multiple Myeloma in Relapse","Non-Hodgkin Lymphoma, B-cell","Non-Hodgkin Lymphoma","Non-Hodgkin Lymphoma (NHL)","Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma","Multiple Myeloma in Remission",[35,30,36,37,38,39,40,41,42,43],"Multiple Myeloma","Refractory","Relapsed","CAR-T","B-cell","Lymphoma","Neoplasms","Lymphoma, B-Cell","Lymphoma, Non-Hodgkin","NOT_YET_RECRUITING","2026-08-14",{"date":47,"type":48},"2026-08-18","ACTUAL",{"date":50,"type":20},"2026-12",{"date":52,"type":20},"2031-02",{"name":54,"class":55},"Luminary Therapeutics","INDUSTRY",{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":84},"100643428","why-patients-decline-or-are-being-deemed-ineligible-to-receive-home-based-treatment-a-mixed-methods-study-100643428","NCT07634263","Why Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods Study","Inclusion Criteria:\n\n* \\>=18 years old\n* diagnosed Multiple Myeloma or acute leukemia, and recieving treatment with either Daratumumab or Cytarabine.\n\nExclusion Criteria:\n\n\\- Dementia, psychotic disorders, or other cognitive impairments limiting participation.","100 Years",{"count":64,"type":20},50,"OBSERVATIONAL","Treatment for blood cancers has improved significantly, and more patients are now living longer. However, these treatments are often intensive and long-lasting, and many patients experience serious side effects and symptoms. As more patients require ongoing treatment and long-term care, the demand for haematology services is increasing.\n\nHome-based treatment is expected to play an increasingly important role in the future. It can support more patient-centred care, help patients maintain their everyday lives, improve quality of life, and reduce pressure on hospitals. Despite these benefits, some patients are either not eligible for home-based treatment or choose to decline it. The reasons for this are not yet well understood.\n\nThis study combines quantitative data-such as medical information, sociodemographic characteristics, and questionnaire responses about quality of life and health literacy-with qualitative interviews involving patients, relatives, and healthcare professionals. The aim is to identify barriers and differences between patients, and to better understand why some patients opt out of or are unable to participate in home-based treatment.\n\nThe findings will help support the development of more inclusive and patient-centred care models, ensure more equal access to home-based treatment, and improve support for socially vulnerable patients. The results will be shared with patients and families through patient organisations, with hospitals through the Treat@Home programme, and at national and international conferences.",[32,68,27],"Multiple Myeloma Progression",[70,71,72,73],"Hematologic Neoplasms","multiple myeloma","Home Care Services","Patient Acceptance of Health Care","2026-06-03",{"date":76,"type":48},"2026-06-08",{"date":78,"type":20},"2026-07-01",{"date":80,"type":20},"2028-06-30",{"name":82,"class":83},"Odense University Hospital","OTHER",3,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":106},"100635851","cognitive-impairment-in-patients-undergoing-cell--and-antibody-based-immunotherapies-for-haematological-malignancies-the-cognitox-study-100635851","NCT07558057","Cognitive Impairment in Patients Undergoing Cell- and Antibody-based Immunotherapies for Haematological Malignancies: The COGNITOX Study","COGNITOX","Inclusion Criteria:\n\n* Patients must be ≥ 18 years old\n* Able to speak and read Danish\n* Provide informed consent\n\nExclusion Criteria:\n\n* CNS-involvement by the haematological malignancy\n* Cognitive impairment due to pre-existing psychiatric or neurological conditions",{"count":93,"type":20},225,"Cell- and antibody-based therapies, including chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies, represent significant advances in the treatment of hematologic malignancies. These therapies optimise the patient's immune system to target and eliminate malignant cells, achieving profound and durable responses in patients where conventional treatment approaches have failed. However, their mechanism of action-through profound immune activation-introduces a challenging toxicity profile, including cytokine release syndrome and immune effector cell-induced neurotoxicity. Emerging evidence suggests that neurotoxicity associated with these therapies may extend beyond acute symptoms to include persistent cognitive impairments. Such impairments can manifest deficits in memory, attention, executive functioning, and processing speed, potentially compromising patients' quality of life, ability to manage daily activities and return to work.\n\nThe COGNITOX project explores the occurrence, clinical manifestations, and impact on quality of life of neuro-psychologically assessed and patient-reported cognitive impairment. The project's data set is generated through standardized neuropsychological tests (recommended by the International Cognition and Cancer) and validated patient reported outcome measures, to evaluate multiple cognitive domains. The project is developed in close collaboration between the Department of Haematology, Aarhus University Hospital and the Unit for Psychooncology and Health Psychology (EPoS), Department of Psychology and Behavioural Sciences, Aarhus University.\n\nThe current literature on cognitive impairment secondary to cell- and antibody-based therapies is limited, and none of the studies reported so far were conducted within a Danish healthcare context. Understanding the prevalence, severity, and functional impact of cognitive impairments in this patient population is critical. These insights will inform clinical practice, guide patient counseling, and support the development of targeted interventions aimed at mitigating cognitive decline. By generating robust data, this project seeks to improve the knowledge within the field and lay the foundation for an intervention study addressing the needs of patients undergoing these advanced immunotherapies.",[96,32],"Malignant Lymphoma - Lymphoplasmacytic","2026-04-22",{"date":99,"type":48},"2026-04-30",{"date":101,"type":20},"2026-03-31",{"date":103,"type":20},"2034-03-31",{"name":105,"class":83},"Aarhus University Hospital",1,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":21,"phases":119,"briefSummary":121,"conditions":122,"keywords":135,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":106},"100624504","phase-1-biomarker-guided-allogeneic-single-target-or-dual-target-car-nk-cell-therapy-for-advanced-solid-tumors-100624504","NCT07410494","Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors","A Phase 1\u002F2, Open-Label, Biomarker-Driven Study of Allogeneic Donor-Derived CAR-NK Cells With Antigen Selection by Tissue Biopsy and\u002For Liquid Biopsy Profiling in Participants With Relapsed\u002FRefractory Advanced Solid Tumors (Single-Target vs Dual-Target Strategy)","SELECT-CAR-NK","Inclusion Criteria:\n\n* Age 18-75 years.\n* Histologically or cytologically confirmed advanced\u002Funresectable or metastatic solid tumor that is relapsed\u002Frefractory after standard therapy, or no standard therapy available.\n* Targetable antigen positivity from the protocol target menu based on:\n\ntissue biopsy and\u002For liquid biopsy platform (as defined in the lab manual).\n\n* Arm assignment rules :\n* Arm A: ≥1 antigen meets \"positive\" threshold\n* Arm B: ≥2 antigens meet \"positive\" threshold\n* ECOG performance status 0-1 (or 0-2 ).\n* At least one measurable lesion by RECIST 1.1.\n* Adequate organ function (hematologic, renal, hepatic, cardiac) within protocol-defined limits.\n* Willingness to undergo blood draws and required biopsies (when medically feasible).\n* Negative pregnancy test for participants of childbearing potential; agreement to effective contraception during and after study treatment.\n\nExclusion Criteria:\n\n* Prior treatment with gene-modified cellular therapy (e.g., CAR-T, CAR-NK) within a defined washout period .\n* Active, uncontrolled infection requiring IV antibiotics; known uncontrolled HIV; active HBV\u002FHCV with detectable viral load (per local policy).\n* Active CNS metastases requiring escalating steroids or urgent intervention (stable treated CNS disease may be allowed ).\n* Active autoimmune disease requiring systemic immunosuppression, or chronic systemic steroids above protocol threshold.\n* Clinically significant cardiovascular disease (e.g., recent MI, unstable arrhythmia), uncontrolled pulmonary disease, or other serious comorbidity that increases risk.\n* Major surgery or anticancer therapy too close to lymphodepletion (protocol-defined washout).\n* Pregnant or breastfeeding.","8 Years","85 Years",{"count":118,"type":20},85,[120,23],"PHASE1","This Phase 1\u002F2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors. The CAR target antigen is selected for each participant after tumor profiling using a tissue biopsy and\u002For liquid biopsy. Participants will receive either a single-target or dual-target CAR-NK product based on the antigen profile.",[123,124,125,126,127,128,129,130,131,132,133,32,134],"Cancer","Breast Cancer","Non-Small Cell Lung Cancer (NSCLC)","Colorectal Cancer (Locally Advanced or Metastatic)","Prostate Cancer - Recurrent","Pancreatic Ductal Adenocarcinoma (PDAC)","Ovarian Cancer","Glioblastoma","Melanoma (Skin Cancer)","Acute Myeloid Leukemia (AML)","Non Hodgkin Lymphoma","Liver Cancer",[136,137,138,139,38,140,141,142,143,144,145,146,147,148,149,150,151],"CAR-NK","Solid tumor","Dual-target CAR","ctDNA","Breast cancer","Non-small cell lung cancer (NSCLC)","Colorectal cancer (CRC)","Prostate cancer","Pancreatic ductal adenocarcinoma (PDAC)","Ovarian, fallopian tube, and primary peritoneal cancers","Glioblastoma and other high-grade gliomas","Melanoma","Acute myeloid leukemia (AML)","Non-Hodgkin lymphoma (NHL), especially DLBCL and follicular lymphoma","Multiple myeloma (especially relapsed\u002Frefractory)","Liver cancer (hepatocellular carcinoma, HCC)","RECRUITING","2026-02-14",{"date":155,"type":48},"2026-02-18",{"date":157,"type":48},"2026-02-01",{"date":159,"type":20},"2028-12-28",{"name":161,"class":83},"Essen Biotech",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":21,"phases":172,"briefSummary":174,"conditions":175,"keywords":181,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":106},"100613720","reduced-dose-apixaban-and-rivaroxaban-versus-low-molecular-weight-heparin-in-patients-with-hematologic-malignancies-100613720","NCT07270263","Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies","Efficacy and Safety of Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies: A Prospective Randomized Study","HEM-DOAC","Inclusion Criteria:\n\n* Active hematologic malignancy at the time of initiation of systemic therapy, including multiple myeloma, myeloproliferative neoplasm, lymphoma or other hematologic cancer with a Khorana score ≥ 2 points (intermediate or high risk of venous thromboembolism, VTE)\n* Use of anticoagulant agents for primary thromboprophylaxis, including direct oral anticoagulants (DOACs) at reduced doses (apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily) or low-molecular-weight heparin (LMWH) (enoxaparin 40 mg subcutaneously once daily).\n\nExclusion Criteria:\n\n* Major bleeding within the last month (including gastrointestinal or intracranial bleeding).\n* Active major bleeding.\n* Hemoglobin concentration \\\u003C 8 g\u002FdL.\n* Thrombocytopenia with platelet count \\\u003C30 × 10⁹\u002FL.\n* ECOG performance status of 3 or 4.\n* Expected survival \\\u003C6 months.\n* History of mechanical heart valve or severe mitral stenosis.\n* Estimated glomerular filtration rate (eGFR) \\\u003C 25 mL\u002Fmin.\n* Hepatic impairment (ALT ≥ 3× upper limit of normal or bilirubin ≥ 2× upper limit of normal).\n* Acute coronary syndrome or ischemic stroke within the last 6 months.\n* Anticipated significant drug-drug interactions between DOACs and anticancer agents.\n* Known antiphospholipid syndrome (APS).",{"count":171,"type":20},100,[173],"NA","This study investigates the efficacy and safety of direct oral anticoagulants (DOACs) in comparison with standard low-molecular-weight heparin (LMWH) for the prevention of venous thromboembolism in patients with hematological malignancies. Eligible participants will be randomized to receive reduced-dose apixaban, reduced-dose rivaroxaban, or standard-dose LMWH. The primary objective is to evaluate the incidence of venous thromboembolism during a 6-month follow-up period. Secondary objectives include assessment of bleeding complications, overall survival, and treatment adherence. The results of this study may provide evidence for safer and more convenient thromboprophylaxis strategies in patients with blood cancers.",[40,176,32,177,178,179,180],"Leukemia","Venous Thromboembolic Disease","VTE (Venous Thromboembolism)","PE - Pulmonary Embolism","Hematologic Malignacies",[182,183,184,185,186,187,188],"Apixaban","Rivaroxaban","Low-Molecular-Weight Heparin","Venous Thromboembolism","Cancer-Associated Thrombosis","Hematologic Malignancies","Direct Oral Anticoagulants","2025-12-18",{"date":191,"type":48},"2025-12-26",{"date":193,"type":48},"2024-11-22",{"date":195,"type":20},"2026-12-31",{"name":197,"class":83},"Medical University of Gdansk",{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":16,"minAge":206,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":209,"conditions":210,"keywords":214,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":231},"100616737","pragmatic-geriatric-assessment-before-car-t-or-bispecific-antibody-therapy-to-predict-side-effects-and-outcomes-in-older-patients-ga-act-trial-100616737","NCT07309497","Pragmatic Geriatric Assessment Before CAR-T or Bispecific Antibody Therapy to Predict Side Effects and Outcomes in Older Patients (GA-ACT Trial)","Pragmatic Geriatric Assessment (pGA) Before Bispecific Antibody and CAR-T-Cell Therapy (GA-ACT Trial) for the Prediction of Toxicity and Outcomes in Older Patients Scheduled for Chimeric Antigen Receptor T-Cell Therapy (CAR-T-Cell-Therapy) or Bispecific Antibody (bsAB) Treatment","GA-ACT","Inclusion Criteria:\n\n* male or female patients age ≥ 65 years,\n* scheduled for CAR-T-cell or bsAB treatments\n* signed informed consent\n* sufficient knowledge of the German or French language\n\nExclusion Criteria:\n\n* inability to understand or sign informed consent\n* refuse to consent","65 Years",{"count":208,"type":20},208,"CAR-T cell or bispecific antibody therapies are a new treatment option for adult patients with aggressive forms of lymphoma or so-called plasma cell diseases ('multiple myeloma', 'plasma cell myeloma') that could not be cured with other, less intensive approaches. However, these are intensive therapies that can be associated with severe and potentially life-threatening side effects. Although there is no age limit for these therapies, we know little about the short- and long-term side effects of these treatments in people of advanced age.\n\nAlthough a small number of patients in the pivotal studies were even over 80 years old, their number was too small to be able to assess the tolerability and success specifically in people over 65. At present, the treating physicians decide whether and, if so, which patients are considered 'fit' enough for this therapy. An objective assessment of the kind we want to investigate in our study does not currently exist on a regular basis. In this study, we therefore want to use simple clinical methods to investigate the effects of these forms of therapy in different areas of everyday function that are important for people in older age (mobility, memory, self-care skills, nutrition). We want to find out whether these investigations help to predict the risk of severe and\u002For long-term side effects. Based on the results, a pragmatic geriatric assessment could be introduced as standard before these therapies. Older patients could thus expect an improvement in their quality of life thanks to more predictable risks and side effects. Standardized screening could lead to lower healthcare costs for treatment and aftercare for both forms of therapy.",[32,211,212,213],"CART Therapy","Bispecific Antibody","Geriatric Hematology",[215,216,71,217,218,219,220,221],"geriatric assessment","lymphoma","bispecific antibodies","chimeric antigen receptor","outcome assessment","toxicity","health related quality of life","2025-12-15",{"date":224,"type":48},"2025-12-30",{"date":226,"type":48},"2025-12-12",{"date":228,"type":20},"2028-02-01",{"name":230,"class":83},"University of Zurich",2,{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":239,"enrollmentInfo":240,"targetDuration":4,"studyType":21,"phases":242,"briefSummary":243,"conditions":244,"keywords":246,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":249,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":106},"100616417","randomised-controlled-trial-of-artificial-intelligence-assisted-health-education-100616417","NCT07305337","Randomised Controlled Trial of Artificial Intelligence-assisted Health Education","The Impact of Artificial Intelligence-Assisted Health Education on Patients' Intention to Participate in Clinical Trials: A Cluster-Randomised Controlled Trial","Inclusion Criteria (1) Aged ≥18 years with clear consciousness; (2) Diagnosed with haematological malignancy meeting clinical treatment criteria (WHO criteria); (3) Capable of understanding health education content and possessing basic communication skills; (4) Willing to participate in this study and sign an informed consent form.\n\nExclusion Criteria\n\n(1) Patients with concomitant cognitive impairment, psychiatric disorders, or other conditions severely affecting comprehension; (2) Anticipated hospital stay of less than 3 days, rendering completion of the intervention unfeasible; (3) End-of-life palliative care; (4) Previous participation in other clinical trial education programmes.","90 Years",{"count":241,"type":20},196,[173],"With the rapid advancement of biopharmaceutical technology, clinical trials have become the crucial bridge connecting new drugs from the laboratory to clinical application. Despite the increasing number of clinical trial projects being conducted, nearly all such projects face the common challenge of recruitment difficulties. Subject recruitment constitutes a pivotal stage in clinical trials; the ability to recruit a sufficient number of subjects meeting the trial requirements significantly impacts trial quality and also serves as a key factor influencing trial progress. Hematologic cancers constitute a highly heterogeneous group of malignant diseases originating in the haematopoietic organs and primarily affecting the haematopoietic system. They encompass acute and chronic leukaemias, malignant lymphomas, multiple myeloma, myelodysplastic syndromes, and related disorders. For patients facing treatment decisions, clinical trials represent not only a vital avenue for accessing cutting-edge therapies but also impose heightened demands on their capacity for informed decision-making. Conversational artificial intelligence (AI) based on large language models is rapidly advancing in health education and public health communication. Medical chatbots offer scalable and personalised advantages in delivering health information, promoting behavioural change, and enhancing patient engagement, providing a viable pathway for improving trial literacy and decision support. Accordingly, this study proposes to conduct a clinical trial literacy intervention using AI-powered chatbots among haematological malignancy patients. Through a randomised controlled trial (RCT), it aims to evaluate the impact of AI-assisted health education on patients' understanding of clinical trials and intention to participate. This research seeks to validate the application value of AI technology in health education and explore scalable AI-assisted health education intervention models.",[245,32,40],"Leukaemia",[245,35,40,247,248],"health education","artificial intelligence",{"date":191,"type":48},{"date":251,"type":48},"2025-06-28",{"date":253,"type":20},"2026-08-30",{"name":255,"class":83},"Zhongnan Hospital"]